This Request for Quotation (RFQ) is issued to identify and select the most suitable service provider for the development and characterization of a final lyophilized NanoGLA nanoformulation, intended for non-GMP preclinical use. This will be necessary to continue with the toxicity studies in second species and to test the efficacy in the final form.
All quotations must be submitted by 25/02/2026 at 23:59 CET to info@delbios.com. Email subject: RFQ-FOR-001-2026
